All Title Author
Keywords Abstract

PLOS ONE  2013 

Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice

DOI: 10.1371/journal.pone.0082082

Full-Text   Cite this paper   Add to My Lib

Abstract:

Recent clinical trials have demonstrated that combination therapy with renin-angiotensin system inhibitors plus calcium channel blockers (CCBs) elicits beneficial effects on cardiovascular and renal events in hypertensive patients with high cardiovascular risks. In the present study, we hypothesized that CCB enhances the protective effects of an angiotensin II type 1 receptor blocker (ARB) against diabetic cerebrovascular-renal injury. Saline-drinking type 2 diabetic KK-Ay mice developed hypertension and exhibited impaired cognitive function, blood-brain barrier (BBB) disruption, albuminuria, glomerular sclerosis and podocyte injury. These brain and renal injuries were associated with increased gene expression of NADPH oxidase components, NADPH oxidase activity and oxidative stress in brain and kidney tissues as well as systemic oxidative stress. Treatment with the ARB, olmesartan (10 mg/kg/day) reduced blood pressure in saline-drinking KK-Ay mice and attenuated cognitive decline, BBB disruption, glomerular injury and albuminuria, which were associated with a reduction of NADPH oxidase activity and oxidative stress in brain and kidney tissues as well as systemic oxidative stress. Furthermore, a suppressive dose of azelnidipine (3 mg/kg/day) exaggerated these beneficial effects of olmesartan. These data support the hypothesis that a CCB enhances ARB-associated cerebrovascular-renal protective effects through suppression of NADPH oxidase-dependent oxidative stress in type 2 diabetes.

References

[1]  Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675. doi:10.1056/NEJMoa010713. PubMed: 11759645.
[2]  Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, K?ber L et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906. doi:10.1056/NEJMoa032292. PubMed: 14610160.
[3]  Parving HH, Lehnert H, Br?chner-Mortensen J, Gomis R, Andersen S et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878. doi:10.1056/NEJMoa011489. PubMed: 11565519.
[4]  Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H et al. (2013) An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int 83: 167-176. doi:10.1038/ki.2012.326. PubMed: 23051740.
[5]  Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2. PubMed: 14656957.
[6]  Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536. PubMed: 17562668.
[7]  Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J et al. (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3-107. PubMed: 19300436.
[8]  Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A et al. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31: 1281-1357. Available online at: doi:10.1097/01.hjh.0000431740.32696.cc. PubMed: 23817082.
[9]  Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A et al. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press 22: 193-278. doi:10.3109/08037051.2013.812549. PubMed: 23777479.
[10]  Turnbull F, Neal B, Ninomiya T, Algert C, Arima H et al. (2008) Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336: 1121-1123. doi:10.1136/bmj.39548.738368.BE. PubMed: 18480116.
[11]  Ravandi A, Teo KK (2009) Blocking the renin-angiotensin system: dual- versus mono-therapy. Expert Rev Cardiovasc Ther 7: 667-674. doi:10.1586/erc.09.47. PubMed: 19505282.
[12]  Jamerson K, Weber MA, Bakris GL, Dahl?f B, Pitt B et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417-2428. doi:10.1056/NEJMoa0806182. PubMed: 19052124.
[13]  Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H et al. (2012) Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 125: 981-990. doi:10.1016/j.amjmed.2011.12.010. PubMed: 22503610.
[14]  Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y et al. (2005) Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 68: 228-236. doi:10.1111/j.1523-1755.2005.00397.x. PubMed: 15954912.
[15]  Hashimoto J, Aikawa T, Imai Y (2008) Large artery stiffening as a link between cerebral lacunar infarction and renal albuminuria. Am J Hypertens 21: 1304-1309. doi:10.1038/ajh.2008.291. PubMed: 18802428.
[16]  Tamura K, Maeda A, Uneda K, Wakui H, Dejima T et al. (2012) An increase in perfusion pressure and activation of the renin-angiotensin system in the pathogenesis of hypertension and injury: strain vessels and the cerebrovascular-renal connection. Hypertens Res 35: 972-974. doi:10.1038/hr.2012.108. PubMed: 22914554.
[17]  Nagasawa T, Mori T, Ohsaki Y, Yoneki Y, Guo Q et al. (2012) Albuminuria indicates the pressure-associated injury of juxtamedullary nephrons and cerebral strain vessels in spontaneously hypertensive stroke-prone rats. Hypertens Res 35: 1024-1031. doi:10.1038/hr.2012.112. PubMed: 22914555.
[18]  Wada M, Nagasawa H, Kurita K, Koyama S, Arawaka S et al. (2007) Microalbuminuria is a risk factor for cerebral small vessel disease in community-based elderly subjects. J Neurol Sci 255: 27-34. doi:10.1016/j.jns.2007.01.066. PubMed: 17320908.
[19]  Kobayashi M, Hirawa N, Morita S, Yatsu K, Kobayashi Y et al. (2010) Silent brain infarction and rapid decline of kidney function in patients with CKD: a prospective cohort study. Am J Kidney Dis 56: 468-476. doi:10.1053/j.ajkd.2010.03.018. PubMed: 20537454.
[20]  Kumai Y, Kamouchi M, Hata J, Ago T, Kitayama J et al. (2012) Proteinuria and clinical outcomes after ischemic stroke. Neurology 78: 1909-1915. doi:10.1212/WNL.0b013e318259e110. PubMed: 22592359.
[21]  Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr., Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330: 1360. doi:10.1136/bmj.38446.466238.E0. PubMed: 15863436.
[22]  Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T et al. (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292: 2237-2242. doi:10.1001/jama.292.18.2237. PubMed: 15536110.
[23]  Serlin Y, Levy J, Shalev H (2011) Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol 2011: 609202.
[24]  Thomas MC, Burns WC, Cooper ME (2005) Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 12: 177-186. doi:10.1053/j.ackd.2005.01.008. PubMed: 15822053.
[25]  Iwai M, Li HS, Chen R, Shiuchi T, Wu L et al. (2006) Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 319: 1081-1087. doi:10.1124/jpet.106.108894. PubMed: 16990512.
[26]  Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y et al. (2012) Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 125: 1402-1413. doi:10.1161/CIRCULATIONAHA.111.064097. PubMed: 22328542.
[27]  Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ et al. (2007) Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 50: 1099-1105. doi:10.1161/HYPERTENSIONAHA.107.099374. PubMed: 17968000.
[28]  Mogi M, Tsukuda K, Li JM, Iwanami J, Min LJ et al. (2007) Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 53: 899-905. doi:10.1016/j.neuropharm.2007.08.020. PubMed: 18028965.
[29]  Avtan SM, Kaya M, Orhan N, Arslan A, Arican N et al. (2011) The effects of hyperbaric oxygen therapy on blood-brain barrier permeability in septic rats. Brain Res 1412: 63-72. PubMed: 21803336.
[30]  Manaenko A, Fathali N, Khatibi NH, Lekic T, Hasegawa Y et al. (2011) Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury. Neurochem Int 58: 542-548. doi:10.1016/j.neuint.2011.01.018. PubMed: 21256175.
[31]  Rafiq K, Nakano D, Ihara G, Hitomi H, Fujisawa Y et al. (2011) Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J Hypertens 29: 290-298. doi:10.1097/00004872-201106001-00824. PubMed: 21243738.
[32]  Sherajee SJ, Fujita Y, Rafiq K, Nakano D, Mori H et al. (2012) Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb Vasc Biol 32: 257-263. doi:10.1161/ATVBAHA.111.240697. PubMed: 22173225.
[33]  Rahman M, Nishiyama A, Guo P, Nagai Y, Zhang GX et al. (2006) Effects of adrenomedullin on cardiac oxidative stress and collagen accumulation in aldosterone-dependent malignant hypertensive rats. J Pharmacol Exp Ther 318: 1323-1329. doi:10.1124/jpet.106.105106. PubMed: 16775197.
[34]  Hoffmann A, Bredno J, Wendland MF, Derugin N, Hom J et al. (2011) Validation of in vivo magnetic resonance imaging blood-brain barrier permeability measurements by comparison with gold standard histology. Stroke 42: 2054-2060. doi:10.1161/STROKEAHA.110.597997. PubMed: 21636816.
[35]  Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I et al. (2010) Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 332: 1072-1080. doi:10.1124/jpet.109.158113. PubMed: 19940106.
[36]  Iwai M, Chen R, Ide A, Iwanami J, Tomochika H et al. (2006) The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens 24: 2023-2031. doi:10.1097/01.hjh.0000244952.54738.f6. PubMed: 16957563.
[37]  Jinno T, Iwai M, Li Z, Li JM, Liu HW et al. (2004) Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 43: 263-269. doi:10.1161/01.HYP.0000113627.08110.6f. PubMed: 14707152.
[38]  Li JM, Iwai M, Cui TX, Min LJ, Tsuda M et al. (2005) Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells. Mol Pharmacol 67: 1666-1673. doi:10.1124/mol.104.008144. PubMed: 15695623.
[39]  Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF et al. (2009) Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 283: 99-106. doi:10.1016/j.jns.2009.02.321. PubMed: 19264328.
[40]  Pelisch N, Hosomi N, Ueno M, Nakano D, Hitomi H et al. (2011) Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens 24: 362-368. doi:10.1038/ajh.2010.241. PubMed: 21164491.
[41]  Lei B, Nakano D, Fan YY, Kitada K, Hitomi H et al. (2012) Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan. J Pharmacol Sci 119: 131-138. doi:10.1254/jphs.12031FP. PubMed: 22673148.
[42]  Sofue T, Kiyomoto H, Kobori H, Urushihara M, Nishijima Y et al. (2012) Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 25: 604-611. doi:10.1038/ajh.2012.1. PubMed: 22318512.
[43]  Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR et al. (2003) Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. Proc Natl Acad Sci U S A 100: 8526-8531. doi:10.1073/pnas.1332809100. PubMed: 12815103.
[44]  Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q et al. (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156. Available online at: doi:10.1212/01.WNL.0000156156.13641.BA. PubMed: 15824339.
[45]  Dobrian AD, Schriver SD, Lynch T, Prewitt RL (2003) Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity. Am J Physiol Renal Physiol 285: F619-F628. PubMed: 12799306.
[46]  Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K et al. (2011) Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res 34: 935-941. doi:10.1038/hr.2011.67. PubMed: 21654755.
[47]  Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820. doi:10.1038/414813a. PubMed: 11742414.
[48]  Goodarzi MT, Navidi AA, Rezaei M, Babahmadi-Rezaei H (2010) Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal 24: 72-76. doi:10.1002/jcla.20328. PubMed: 20333759.
[49]  Suzuki J, Iwai M, Li Z, Li JM, Min LJ et al. (2005) Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 23: 1383-1389. doi:10.1097/01.hjh.0000173521.91104.5f. PubMed: 15942461.
[50]  Kondo N, Kiyomoto H, Yamamoto T, Miyatake A, Sun GP et al. (2006) Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats. J Pharmacol Exp Ther 316: 1047-1052. PubMed: 16319305.
[51]  Selvakumar K, Prabha RL, Saranya K, Bavithra S, Krishnamoorthy G et al. (2013) Polychlorinated biphenyls impair blood-brain barrier integrity via disruption of tight junction proteins in cerebrum, cerebellum and hippocampus of female Wistar rats: neuropotential role of quercetin. Hum Exp Toxicol 32: 706-720. doi:10.1177/0960327112464798. PubMed: 23155198.
[52]  Venkataraman P, Krishnamoorthy G, Vengatesh G, Srinivasan N, Aruldhas MM et al. (2008) Protective role of melatonin on PCB (Aroclor 1,254) induced oxidative stress and changes in acetylcholine esterase and membrane bound ATPases in cerebellum, cerebral cortex and hippocampus of adult rat brain. Int J Dev Neurosci 26: 585-591. doi:10.1016/j.ijdevneu.2008.05.002. PubMed: 18555635.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal